| abstract |
New heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; atherosclerosis; Cancer; cachexia; ischemic damage induced by the destruction of cells; destruction of the beta cells of the pancreas; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD, bone resorption diseases; multiple sclerosis; sepsis, septic shock; Toxic shock syndrome and fever. Specifically, these compounds are useful as PDE4 inhibitors and are useful for the treatment of PDE4 mediated diseases. |